[go: up one dir, main page]

WO1988009797A1 - Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer - Google Patents

Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer Download PDF

Info

Publication number
WO1988009797A1
WO1988009797A1 PCT/US1988/001805 US8801805W WO8809797A1 WO 1988009797 A1 WO1988009797 A1 WO 1988009797A1 US 8801805 W US8801805 W US 8801805W WO 8809797 A1 WO8809797 A1 WO 8809797A1
Authority
WO
WIPO (PCT)
Prior art keywords
amf
motility
cells
cell
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1988/001805
Other languages
English (en)
Inventor
Lance A. Liotta
Elliott Schiffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
Original Assignee
United States Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Commerce filed Critical United States Department of Commerce
Publication of WO1988009797A1 publication Critical patent/WO1988009797A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Definitions

  • the present invention is related generally to the field of cancer diagnosis and management. More particularly, the present invention is related to novel tumor motility factors and their utility in devising new approaches to cancer diagnosis, prevention and therapy.
  • an object of the present invention to identify and provide an autocrine factor controlling motility of tumor cells, such autocrine factor being designated herein as "AMF.” It is a further object of the present invention to provide antibodies having specific binding affinity for AMF or AMF receptors. It is a still further object of the present invention to provide a kit for detecting, localizing and predicting metastases and tumor angiogenesis in humans. It is yet another object of the present invention to provide a method of predicting, preventing and/or treating metastatic invasion and cancer proliferation in humans. It is an additional object of the present invention to provide a pharmaceutical composition comprising an effective amount of neutralizing antibodies against AMF to inhibit motility of tumor cells in a pharmaceutically acceptable carrier.
  • Fig. 1 shows a schematic representation of the Boyden test
  • Fig. 2 shows (a) Scatchard analysis of 125 I-AMF binding to suspended tumor cells; and (b) dose response curve of cell motility to purified AMF.
  • polypeptide having the following properties: (a) secreted by mammalian cells and stimulates random locomotion of the producer cells; (b) having molecular weight of > 30,000; and (c) being inhibited by pertussis toxin.
  • the polypeptide of the present invention is found to have, at least in part or in whole, the following amino acid sequence at its NH2 terminus (single letter code) or at the NH2 terminus of an active fragment of the polypeptide :
  • MDA231 and MDA435 breast carcinoma cells lines were obtained from ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. Both of these estrogen independent cell lines produce metastases in the lungs of a 6 week-old NIH nude mice, 6 weeks following injection of 5 x 10*5 cells into the lateral tail vein.
  • DMEM Dulbecco's modified Eagle's medium
  • Elution with PBS yields an active fraction that corresponds to material with a molecular weightof about 54 kDa.
  • This fraction is dialyzed and concentrated 25 fold.
  • the material is made up to 50 mM Tris-acetate, pH 8.0 and applied to a mono Q anion exchange column (source) and eluted with a linear salt gradient (0-1 M NaCl) with the following modification: When the NaCl concentration reaches 0.25 M, this concentration is held for 10 min before resuming the gradient.
  • AMF is eluted in the 0.3 M to 0.4 M NaCl fraction.
  • the active fraction is dialyzed and concentrated to a small volume (about 0.5 ml) which in turn is made up to 0.02 M phosphate in normal saline, pH 7.4.
  • the assay of motility is accomplished by the use of a modified Boyden (Zigmond, et al, J. Exp. Med. 137:387-410, 1973) chamber.
  • This is a device ( Figure 1) consisting of 2 wells horizontally separated by a microporous polycarbonate filter with a pore diameter of about 8 u.
  • the motility stimulus (or chemoattractan ) is placed in the lower well to contact the filter.
  • To the upper well is added a -suspension of cells (for example A2085 melanoma cells) at a concentration of about 10 ⁇ cells/ml.
  • the chamber is then placed in a humidified incubator for about 4 hours at 37 degrees C in an atmosphere of air and about 5% CO2. During this time, the cells are deposited by gravity on the topside of the filter. However, some cells (about 5 to 10%) migrate to the underside of the filter in response to the motility stimulant. Expenditure of energy must occur during migration since the average diameter of the cell is greater than the pore size diameter.
  • the filter is removed and subjected to a fixing and staining procedure. This includes first immersing the filters in a methanol-containing solution for about 2 minutes; then in an eosin solution for about 2 minutes; and then in a hematoxylin solution for about 3 minutes.
  • the filters are washed in water and placed on a glass slide with the topside up.
  • the buttons of stained cells on the topside are completely removed with a small piece of dry tissue paper.
  • the stained cells that have migrated through the filter then become apparent. These are counted with the aid of a microscope at a magnification of about 500X.
  • Five different high power fields are visualized with a grid in one ocular, the cells in 5 fields are counted and the average is computed.
  • a ratio of _5 for positive control/negative control is indicative of a positive response of the cells to the motility stimulus.
  • Random and Directed Motility Measurement of random motility is accomplished by exposing the cells to a fixed concentration of stimulus and determining their migration as described above. This includes adding equal increasing concentrations of attractant to both upper and lower wells prior to the assay incubation. The random migration of cells as a function of the levels of attractant is then determined. Directed migration occurs if the cells migrate better in - 7 -
  • DMEM supplements with L-glutamine (2 ⁇ g), penicillin and streptomycin with or without 10% heat-inactivated fetal calf serum were purchased from commercial sources such as Meloy Laboratories, Inc. (Springfield, VA). Pertussis toxin and cholera toxin were obtained from List Biological Laboratories, Inc. (Cambell, CA).
  • Phorbol 12-myristate 13-acetate (PMA), phorbol 12, 13-didecanoate (PDD), calcium ionophore A23187, diltiazem, nifedipine, verapamil, trifluoperazine, leupeptin, forskolin and 8-Br cAMP were all purchased from Sigma Chemical Company (St. Louis, MO).
  • the l-oleoyl-2-acetylglycerol was from Molecular Probes (Eugene, OR).
  • the Nucleopore membranes (polyvinyl- pyrrolidone-free) as well as the 48-well chemotaxis chamber were purchased from Neuro Probe, Inc. (Cabin- John, MD).
  • A2058 melanoma cells (approximately 75-90% confluent) were .harvested with trypsin-EDTA and allowed to recover at room temperature in DMEM supplemented with 10% fetal calf serum for at least one hour. The cells were then resusoended at 2 x 10 ⁇ /ml in DMEM with 1 mg/ml bovine serum albumin. The assay was performed in 48-well micro-chemotaxis chamber (Harvath et al, 1980 supra) with 8 ⁇ m Nucleopore membranes coated with type IV collagen. The chambers were incubated at 37 degrees C for 4-5 hours, then developed using Diff Quick stains (American Scientific).
  • the stained membranes were placed onto glass slides with the original cell side up so that the cell pellet could be wiped from the surface. Cells that had migrated through the pores were trapped between glass and membrane and could be easily counted by light microscopy under high power field (500X). Unstimulated random migration was ⁇ 20% of directed migration.
  • chemicals Prior to or during the chemotaxis assay, chemicals could be co-incubated with cells to alter cellular metabolism or stimulate a chemokinetic response. At the start of the assay, chemicals could also be added to the lower chamber to demonstrate chemotactic potential.
  • AMF protein (10 ⁇ g) was emulsified with complete Freund's adjuvant and injected into the foot pad of 3 C3H mice. Two weeks later the mice were boosted with 5 ug of AMF in PBS injected intravenously in the tail vein in a volume of 0.1 ml. One month later the mice were bled and the serum was tested for its ability to inhibit tumor cell motility. In this assay the mouse sera was preincubated with the AMF in the Boyden chamber migration assay. At a dilution of 1/1000 the mouse sera produced 90% inhibition of tumor cell motility compared to pooled mouse sera control.
  • Purified AMF protein (10 ⁇ g) was emulsified in complete Freundi ' s adjuvant and injected- into a subcutaneous site on the back of New Zealand white rabbits. Booster injections of 5 ⁇ g were applied at 6 and 12 weeks. At 3 and 4 months the rabbits were bled and the sera was tested for motility inhibition activity. At a dose of 1/1000 the immune sera abolished motility compared to control preimmune sera. The sera were heat inactivated at 56°C for 30 minutes.
  • the purity of the isolated AMF was determined by the following criteria: (a) Single 54 kDA band was found on a single and two dimensional polyacrylamide gel electrophoresis performed by standard procedures well known in the art. Protein was identified with silver stain. (b) Protein band cut from the gel retains motility stimulating activity. (c) NH2 terminus amino acid sequence (1-19) reveals one "type of amino acid residue at each cycle; and (d) Murine and rabbit anti-AMF antibodies block the motility stimulating activity of human tumor AMF. Based on the above criteria, the isolated AMF of the present invention was found to be substantially pure. The term "substantially" as used herein means as pure as it is possible to obtain by standard techniques.
  • Cholera Toxin in contrast to pertussis toxin, is thought to act on the G s protein that stimualtes adenylate cyclase to produce the second messenger, cAMP. Cholera toxin was added to A2058 cells either for overnight incubation in flasks or for variable periods of preincubation prior to the start of the chemotaxis assay. The tested doses of cholera toxin ranged from about 0.1-50 ⁇ g/ml.
  • Cholera toxin is thought to act by ADP-ribosylation of the G s protein in an active configuration that can stimulate adenylate cyclase. Since the effect of cholera toxin on A2058 cell motility was minimal, further tests were conducted to determine whether other agents that act on the cAMP pathyway would be inhibitory. Forskolin stimulates adenylate cyclase directly without acting through an intermediary G protein. The cAMP analogue, 8-Br cAMP, is able to enter intact cells.
  • the migration-stimulating material of the present invention is found to have a molecular weight of about 54 kilodaltons. This form may be a precursor of an active factor. It is possible that cellular or serum components could activate or inhibit the action of the motility factor.
  • the motility factor is inactivated by exposure to streptococcal protease, but active chymotrypsin-derived fragments can be produced (data not shown). The activity is destroyed by boiling but- is stable upon exposure to 56 degrees C.
  • the activity is stable to a pH range from 4 to 11 (data not shown).
  • AMF autocrine material
  • known growth factors such as PDGF, c ⁇ TGF, ⁇ TGF, EGF, IGF, transferrin, or FGF do not substitute or block the AMF (data not shown).
  • Amino acid analysis indicated a unique sequence of 19 amino terminal amino acids of AMF.
  • a slightly small form of the active material was also found to have a unique amino terminal sequence. Protein data base searches failed to reveal any other polypeptide with such a sequence. It has also been found that motility induction by AMF is not blocked or substituted by known growth factors or serum factors.
  • AMF markedly stimulates the random and directed motility of breast cancer cells but fails to induce motility in leukocytes.
  • the factor also stimulated random pseudopodia production by breast carcinoma cells and melanoma cells.
  • AMF and its receptor are enhanced more than 100 fold in certain cells.
  • Antibodies recognizing AMF abolish human tumor cell motility in vitro without altering tumor cell viability.
  • the availability of an isolated and purified autocrine, polypeptide, tumor motility factor makes it possible to obtain anti-AMF antibodies having specific binding affinity for said motility factor.
  • Such antibodies can either be polyclonal or monoclonal and are prepared by well known standard techniques routine in the art. Such antibodies can also be labelled with suitable radioisotopes or fluorescent and other markers or ligands and employed for the detection, quantitation and/or localization of the AMF in human tissue or body fluid. Furthermore, radiolabelled AMF together with unlabelled AMF can be utilized in a standard competitive assay to measure AMF receptor level. Such binding assay for determining the receptor level is carried out as follows. AMF Binding Assay: Purified AMF is iodinated using the standard " Bio Rad enzymobead procedure.
  • AMF binding exhibits saturation with 80% specific * binding and about 30,000 receptors per cell.
  • Scatchard analysis according to standard methods shows a linear relationship between the specifically bound/free ratio and the specifically bound .AMF, with an estimated kd in the range of about 0.5 nM. Detection of cancer in humans is also made possible by the present discovery and testing of human body samples for this purpose is now illustrated using urine samples from bladder cancer patients.
  • Urine samples from patients with bladder cancer are collected and processed with centrifugal microconcentrator (AMICON) with an exclusion filter of 10 kilodaltons.
  • the processed urines are reconstituted at a 10-fold concentration with steriel phosphate buffered saline pH7.5 and stored at -20°C until use.
  • Tumor grade is determined by a pathologist using a scale of one to three with grade one tumors showing the most differentiation and grade three tumors showing the least differentiation.
  • Bladder tumors are staged according to ' , the American Joint Committee TNM classification.
  • the preferred cell line is human MDA 435 cells (ATCC).
  • ATCC human MDA 435 cells
  • the concentrated urine samples are applied to the microwell migration chamber assay as described herein supra. Each sample is tested at a series of dilutions with and without the addition of the antibodies directed against human tumor AMF.
  • AMF units are recorded as the proportion of tumor cells stimulated to migrate by the sample which is inhibited by the antibodies. In general, greater than 80% of the stimulated migration is inhibited by an antibody concentration of about 10 ⁇ g/ml.
  • control urines with non-neoplastic disorders such as kidney stones failed to contain significant levels of motility factors. All of the bladder transitional cell carcinoma cases exhibited a positive motility response in the urine. The highest levels of motility factor production was found in the urine of patients with high grade tumors or with stage D (metastatic) tumors.
  • TCC Transitional cell carcinoma of the bladder
  • TCC stg D metastatic TCC
  • the antibodies against AMF can be employed to block or inhibit AMF activity thereby arresting tumor invasion or metastatic proliferation which depend on tumor cell motility.
  • Availability of such neutralizing antibodies also makes it possible to treat such conditions as breast carcinoma and melanoma by administering to a person inflicted with these conditions, an effective amount of the AMF-antibodies to prevent these conditions from progressing.
  • a pharmaceutical composition for treating cancer and metastases is prepared by simply including an effective amount of neutralizing antibodies against AMF to inhibit motility of tumor cells and a pharmaceutically acceptable carrier such as physiological saline, non-toxic buffers and the like.
  • kits for detecting tumor aggressiveness and/or metastatic activity comprising separate containers containing (a) antibodies having specific binding affinity for AMF; (b) labelled AMF; (c) unlabelled AMF and instructional material for performing tests utilizing the antibodies and the AMF provided in the kit for determining AMF and/or receptor activity in a body sample.
  • Such accessories as microtiter plates, micropipettes, means for reading antibody titer and the like are routinely found in such kits and may be included for convenience in the kits of the present invention.
  • the present invention provides a new tool for understanding mechanisms which control tumor cell invasion and opens new strategies for cancer diagnosis and therapy. Epithelial cells do not normally exhibit invasive behavior.
  • the motility factor described herein does not affect the migration of normal blood leukocytes. Therefore, a therapeutic agent aimed at inhibiting the factor described in the invention should have low toxicity against normal resting tissues.
  • Pharmacologic preparations obtained in accordance with the present invention which inhibit invasion of tumor cells and prevent the transition from in situ to invasive carcinoma could be potent cancer arresting agents. Inhibitors of tumor invasion can also prevent the growth of established metastases because a metastasis may need to invade locally as it grows. Furthermore, such agents may inhibit tumor angiogenesis.
  • Antibodies to motility factors or their receptors could be applied through tissue immunohistology, radioscintography, or serum immunoassays to localize metastases and predict cancer aggresseiveness in individual patients.
  • autocrine motility factors or their receptors define a new class of oncogenes.
  • the level of expression of these genes in a patient's tumor may provide important diagnostic information through monitoring the level of AMF in the body sample.
  • invasion and metastases are among the major causes of cancer treatment failure.
  • the present invention provides new clinical strategies to (a) detect pre-invasive lesions and prevent their progression; (b) accurately predict the aggressiveness of a patient's tumor, and (c) identify and eradicate micrometastases.
  • One of the least understood aspects of tumor invasion is tumor cell locomotion.
  • the present invention allows the determination of the role of the tumor cell motility factor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Polypeptide cellulaire mammifère isolé et quasiment pur qui stimule la locomotion aléatoire de la cellule productrice et qui présente un poids moléculaire supérieur à 30.000. Ce polypeptide extraordinaire est inhibé par la toxine de la coqueluche. Sont également décrits un kit et un procédé pour détecter la métastase chez l'homme.
PCT/US1988/001805 1987-06-05 1988-05-27 Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer Ceased WO1988009797A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5838187A 1987-06-05 1987-06-05
US058,381 1987-06-05

Publications (1)

Publication Number Publication Date
WO1988009797A1 true WO1988009797A1 (fr) 1988-12-15

Family

ID=22016462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/001805 Ceased WO1988009797A1 (fr) 1987-06-05 1988-05-27 Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer

Country Status (6)

Country Link
EP (1) EP0362278A4 (fr)
JP (1) JP2851288B2 (fr)
AU (1) AU614755B2 (fr)
CA (1) CA1310902C (fr)
IL (1) IL86577A (fr)
WO (1) WO1988009797A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014202A1 (fr) * 1992-01-17 1993-07-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autotaxine: proteine stimulant la motilite, utilisee pour le diagnostic et la therapie du cancer
EP0656114A4 (fr) * 1992-07-14 1998-07-08 Michigan Cancer Foundation Procede pour determiner le potentiel metastatique de cellules tumorales.
WO1999061060A1 (fr) * 1998-05-22 1999-12-02 Universite De Montreal Conjugues de ligand d'amf et d'une molecule cytotoxique pouvant etre utilises dans la therapie du cancer
DE19847107A1 (de) * 1998-10-13 2000-04-20 Herbert Ruebben Verwendung von Pertussistoxin zur Behandlung von Tumorerkrankungen
WO2001074897A3 (fr) * 2000-04-03 2002-06-20 Curagen Corp Proteines et acides nucleiques codant pour lesdites proteines
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US8425913B2 (en) 2005-09-30 2013-04-23 The Secretary Of State Of Defence Immunogenic agents against Burkholderia pseudomallei and/or Burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from Burkholderia pseudomallei
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella
US8778356B2 (en) 2009-01-13 2014-07-15 The Secretary Of State For Defence Vaccine

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) * 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
EP1755666B1 (fr) 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
EA011419B1 (ru) 2005-03-23 2009-02-27 Глаксосмитклайн Байолоджикалс С.А. Поливалентная противогриппозная иммуногенная композиция
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2006327040B2 (en) 2005-12-22 2010-08-19 Glaxosmithkline Biologicals Sa Vaccine comprising Streptococcus pneumoniae capsular polyaccharide conjugates
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
DK2422810T3 (da) 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
WO2008009650A2 (fr) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccins contre le paludisme
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
EP2433648A3 (fr) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccin comprenant une émulsion adjuvante huile en l'eau
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP2010531330A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
US10040825B2 (en) 2007-12-19 2018-08-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
MX2010011412A (es) 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011117408A1 (fr) 2010-03-26 2011-09-29 Glaxosmithkline Biologicals S.A. Vaccin contre le hiv
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2707025B8 (fr) 2011-05-13 2017-08-23 Zoetis Services LLC Compositions immunogènes contre la glycoprotéine g des virus hendra et nipah
AR086405A1 (es) 2011-05-17 2013-12-11 Glaxosmithkline Biolog Sa Vacuna de streptococcus pneumoniae
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
SG11201503861UA (en) 2012-12-05 2015-06-29 Glaxosmithkline Biolog Sa Immunogenic composition
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN105828836A (zh) 2013-12-16 2016-08-03 硕腾服务有限责任公司 亨德拉病毒和尼帕病毒g糖蛋白免疫原性组合物
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018198085A1 (fr) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
EP3581201A1 (fr) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptides et leurs utilisations
WO2019245266A1 (fr) * 2018-06-20 2019-12-26 박희성 Composition anticancéreuse contenant en tant que principe actif une cytokine issue de cancers, l'amf
WO2020026147A1 (fr) 2018-07-31 2020-02-06 Glaxosmithkline Biologicals Sa Procédé de purification d'antigène
US11547672B2 (en) 2018-09-14 2023-01-10 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
WO2020109365A1 (fr) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
US12419950B2 (en) 2019-03-19 2025-09-23 The Uab Research Foundation Saponin-based vaccine adjuvants
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP4028051A1 (fr) 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Compositions immunothérapeutiques
WO2021099982A1 (fr) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage et administration d'un vaccin à base de glycoconjugué de saccharide bactérien
EP4077356A1 (fr) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA Antigènes de s. aureus et compositions associées
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
WO2022029024A1 (fr) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa PROTÉINE FUSOBACTERIUM ADHÉSINE A (FadA) DE FUSOBACTERIUM NUCLEATUM TRONQUÉE ET COMPOSITIONS IMMUNOGÈNES À BASE DE CELLE-CI
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
AU2021392894B2 (en) 2020-12-02 2024-09-19 Glaxosmithkline Biologicals Sa Donor strand complemented fimh
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023114570A1 (fr) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions et méthodes pour obtenir des réponses durables des centres germinatifs à une sensibilisation active
MX2024010416A (es) 2022-03-14 2024-09-05 Pfizer Metodos de produccion de un adyuvante.
TW202517297A (zh) 2023-09-13 2025-05-01 美商輝瑞股份有限公司 產製佐劑之方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, Vol. 146, No. 1, issued July 1987, pages 339-345, (STRACKE) "Pertussis Toxin Inhibits Stimulated Motility Independently of the Adenylate Cyclase Pathway in Human Melanoma Cells" (Bethesda, MD.) see summary. *
CHEMICAL ABSTRACT, Vol. 105 issued July 1986 (Columbus, OH) Abstract No. 22367p (LIOTTA) "Tumor Autocrine Motility Factor" *
CHEMICAL ABSTRACT, Vol. 108, issued February 1988, (Columbus, OH.) Abstract No. 53562q. (LIOTTA) "Biochemical Mechanisms of Tumor Invasion and Metastasis" *
CHEMICAL ABSTRACT, Vol. 108, issued January 1988, (Columbus, OH.) Abstract No. 19880g (GUIRGUIS) "Cytokine-Induced Pseudopodial Protrusion is Couple to Tumor Cell Migration" *
Proceeding National Academy of Science, Vol. 83, pages 3302-3306, issued May 1986, (LIOTTA) "Tumor Cell Autocrine Motility Factor" see Abstract. (Washington, D.C.) *
See also references of EP0362278A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014202A1 (fr) * 1992-01-17 1993-07-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autotaxine: proteine stimulant la motilite, utilisee pour le diagnostic et la therapie du cancer
EP0656114A4 (fr) * 1992-07-14 1998-07-08 Michigan Cancer Foundation Procede pour determiner le potentiel metastatique de cellules tumorales.
WO1999061060A1 (fr) * 1998-05-22 1999-12-02 Universite De Montreal Conjugues de ligand d'amf et d'une molecule cytotoxique pouvant etre utilises dans la therapie du cancer
DE19847107A1 (de) * 1998-10-13 2000-04-20 Herbert Ruebben Verwendung von Pertussistoxin zur Behandlung von Tumorerkrankungen
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US8628784B2 (en) 1998-10-16 2014-01-14 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
WO2001074897A3 (fr) * 2000-04-03 2002-06-20 Curagen Corp Proteines et acides nucleiques codant pour lesdites proteines
US8425913B2 (en) 2005-09-30 2013-04-23 The Secretary Of State Of Defence Immunogenic agents against Burkholderia pseudomallei and/or Burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from Burkholderia pseudomallei
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US8790910B2 (en) 2006-07-25 2014-07-29 The Secretary Of State For Defence Live vaccine strain
US8778356B2 (en) 2009-01-13 2014-07-15 The Secretary Of State For Defence Vaccine
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella

Also Published As

Publication number Publication date
IL86577A (en) 1993-06-10
EP0362278A4 (fr) 1990-05-14
AU614755B2 (en) 1991-09-12
JPH04502143A (ja) 1992-04-16
JP2851288B2 (ja) 1999-01-27
AU1803488A (en) 1989-01-04
CA1310902C (fr) 1992-12-01
IL86577A0 (en) 1988-11-15
EP0362278A1 (fr) 1990-04-11

Similar Documents

Publication Publication Date Title
CA1310902C (fr) Facteurs autocrines de motilite pour le diagnostic et le traitement du cancer
Shoji et al. Bronchial epithelial cells produce lung fibroblast chemotactic factor: fibronectin
JP2598362B2 (ja) 肝成長因子受容体としてのｍｅｔプロトオンコジーン
US5888965A (en) Method of stimulating bone marrow regeneration
Le et al. Acute phase reactants of mice. I. Isolation of serum amyloid P-component (SAP) and its induction by a monokine.
US6025333A (en) Treatment of CNS tumors with metalloprotease inhibitors
Kochi et al. Immunohistochemical study of fibronectin in human glioma and meningioma
US5385740A (en) Biologically active material characterized by catabolic activity generally associated with cachexia-inducing tumors, preparations, production and uses thereof
JP2013177395A (ja) 哺乳動物を治療して体重減少又は肥満の減少を生じさせる方法
JP2002539174A (ja) 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
US20110039279A1 (en) Methods and compositions for diagnosing breast cancer
Schaudies et al. Increased soluble EGF after ischemia is accompanied by a decrease in membrane-associated precursors
Beguinot et al. Functional studies on the EGF receptor with an antibody that recognizes the intracellular portion of the receptor.
Miyake et al. Cell union and protein synthesis in conjugation of Blepharisma
Riopelle et al. Serum neuronal growth factor levels in von Recklinghausen's neurofibromatosis
US20040072189A1 (en) Prognostic indicator
US5580968A (en) DNA encoding phospholipase activating protein
JPH06508111A (ja) 甲状腺由来の軟骨細胞刺激因子
Johansson et al. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment.
JPH06504285A (ja) ニューロンコリン作動性分化因子
Eckert et al. AM r 43,000 Epidermal Growth Factor-related Protein Purified from the Urine of Breast Cancer Patients
AU593063B2 (en) Purified human angiogenic factor, method for its preparation and pharmaceutical preparations
Arvanitis et al. Reactive astrocytes upregulate one or more gene products that are recognized by monoclonal antibody H
EP0646600B1 (fr) Protéine inhibant la croissance cellulaire
WO1993016715A1 (fr) Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988905318

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988905318

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988905318

Country of ref document: EP